Chimeric antigen receptor (CAR) tregs against pan class i swine leukocyte antigen and uses thereof

WO2026064255A1PCT designated stage Publication Date: 2026-03-26THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
View PDF 6 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-09-16
Publication Date
2026-03-26

AI Technical Summary

Technical Problem

The challenge of controlling immune responses in xenotransplantation without excessive toxicity and addressing the plasticity of chimeric antigen receptor (CAR) Tregs, as well as the effects of T cell-depleting conditioning regimens, remains a significant hurdle in clinical application.

Method used

Development of modified Treg cells with a chimeric antigen receptor (CAR) comprising a class-I swine leukocyte antigen-binding domain, a transmembrane domain, and an intracellular signaling domain, including stimulatory and/or co-stimulatory molecule signaling, to induce immune tolerance against pig antigens and suppress immune responses.

Benefits of technology

The modified Treg cells effectively prevent immune rejection of pig organs, reducing the likelihood of graft versus host disease and host versus graft disease, providing a stable and potent immune response suppression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025046472_26032026_PF_FP_ABST
    Figure US2025046472_26032026_PF_FP_ABST
Patent Text Reader

Abstract

Compositions and methods for suppressing rejection of xenotransplants are provided herein, including compositions comprising modified Treg cells that comprise a chimeric antigen receptor (CAR), wherein the CAR comprises a class-I swine leukocyte antigen-binding domain, a transmembrane domain, and an intracellular signaling domain, and methods for generating and using such modified Treg cells.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Alternative pathway specific antibodies for treating arthritis

    US20160207987A1

  • Car t cells that target b-cell antigens

    US20210205362A1

  • Enhanced CAR Tregs and Bi-Specific Antibodies for Induction of Immune Tolerance, Treating Autoimmune Diseases and Preventing Transplantation Rejection

    US20210268023A1

  • Fusion protein for use in the treatment of hvg disease

    US20220133796A1

  • Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens

    US20240034806A1